Risk minimisation material: Caprelsa (vandetanib)- Healthcare professional cover letter

Letter warns of potential significant adverse effects that healthcare professionals should be aware of, such as QTC prolongation, and sudden death and posterior reversible encephalopathy syndrome. Also a dosing and monitoring guide for paediatric patients is provided.

SPS commentary:

A patient guide and alert card have been produced in conjunction


electronic Medicines compendium

Resource links:

Patient Guide

Patient alert card